Li Jing Pacific (00575.HK) announced on the evening of December 18 that the company's strategic partner Jiangsu Wanbang Pharmaceutical submitted Sensend's new drug application to the State Drug Administration on December 18 and is expected to be approved within 12 months from submission. Senstend is a new drug developed by Regent Pacific, which is mainly used to treat premature ejaculation in men. When the drug is approved by the State Drug Administration and the first domestic commercial sale is carried out, Jiangsu Wanbang Pharmaceutical will pay 5 million US dollars and 2 million US dollars respectively to Regent Pacific, and then pay a milestone payment of up to 25 million US dollars based on sales.